Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
复制标题
木犀草素通过调节 MicroRNA-34a-5p 抑制肿瘤发生并诱导非小细胞肺癌细胞凋亡
DOI:
10.3390/ijms19020447
复制
发表时间:
2018-02-02
影响因子:
5.6
通讯作者:
Wu MH
中科院分区:
文献类型:
--
作者:
Jiang ZQ;Li MH;Qin YM;Jiang HY;Zhang X;Wu MH
Luteolin (LTL) exerts remarkable tumor suppressive activity on various types of cancers, including non-small cell lung cancer (NSCLC). However, it is not completely understood whether the mechanism of its action against NSCLC is related to microRNAs (miRNAs). In the present study, we investigated the anti-tumor effects of LTL on NSCLC in vitro and in vivo. The results revealed that LTL could inhibit cell proliferation and induce apoptosis in both A549 and H460 cells. In a H460 xenograft tumor model of nude mice, LTL significantly suppressed tumor growth, inhibited cell proliferation, and induced apoptosis. miRNA microarray and quantitative PCR (qPCR) analysis indicated that miR-34a-5p was dramatically upregulated upon LTL treatment in tumor tissues. Furthermore, MDM4 was proved to be a direct target of miR-34a-5p by luciferase reporter gene assay. LTL treatment was associated with increased p53 and p21 protein expressions and decreased MDM4 protein expression in both NSCLC cells and tumor tissues. When miR-34a-5p was inhibited in vitro, the protein expressions of Bcl-2 and MDM4 were recovered, while that of p53, p21, and Bax were attenuated. Moreover, caspase-3 and caspase-9 activation induced by LHL treatment in vitro were also suppressed by miR-34a-5p inhibition. Overall, LTL could inhibit tumorigenesis and induce apoptosis of NSCLC cells by upregulation of miR-34a-5p via targeting MDM4. These findings provide novel insight into the molecular functions of LTL that suggest its potential as a therapeutic agent for human NSCLC.
登录
查看更多内容
影响因子:
--
作者:
Brentnall M;Rodriguez-Menocal L;De Guevara RL;Cepero E;Boise LH
通讯作者:
Boise LH
DOI:
10.1007/978-3-319-24932-2_8
发表时间:
2016-01-01
期刊:
LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT
影响因子:
--
作者:
Hussain, Sajid
通讯作者:
Hussain, Sajid
影响因子:
3.2
作者:
Cai, Xueting;Ye, Tingmei;Cao, Peng
通讯作者:
Cao, Peng
影响因子:
64.8
作者:
He, Lin;He, Xingyue;Hannon, Gregory J.
通讯作者:
Hannon, Gregory J.
DOI:
10.1016/j.bbrc.2016.01.002
发表时间:
2016-01-29
影响因子:
3.1
作者:
Choi, Hee-Jin;Choi, Hee-Jung;Ha, Ki-Tae
通讯作者:
Ha, Ki-Tae